Kaken Pharmaceutical Co Ltd 2022 IR
The report outlines Kaken Pharmaceutical Co., Ltd.'s business performance and sustainability initiatives for the fiscal year 2021. Key highlights include the formulation of the Long-Term Business Plan 2031, which focuses on three major transformations: R&D, overseas expansion, and management base. The company acquired ARTham Therapeutics Inc. to expand its development pipeline in dermatology and orthopedics. Additionally, Kaken established a new Sustainability Policy in May 2022 to integrate ESG principles into its core operations, emphasizing environmental management, human resource development, and corporate governance.
Company: Kaken Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2022
Type: IR
Pages: 43
Kaken Pharmaceutical Co Ltd
Corporate Report
The report outlines Kaken Pharmaceutical Co., Ltd.'s business performance and sustainability initiatives for the fiscal year 2021. Key highlights include the formulation of the Long-Term Business Plan 2031, which focuses on three major transformations: R&D, overseas expansion, and management base. The company acquired ARTham Therapeutics Inc. to expand its development pipeline in dermatology and orthopedics. Additionally, Kaken established a new Sustainability Policy in May 2022 to integrate ESG principles into its core operations, emphasizing environmental management, human resource development, and corporate governance.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Apr 1, 2021 - Mar 31, 2022
Fiscal Year
2021
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Net Zero Target
Employees